argenx SE
ARGXNASDAQFcRn antibody technology
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
No upcoming catalyst for argenx SE has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Vyvgart | Generalized Myasthenia Gravis | Approved | Not disclosed | ▼ |
| Vyvgart Hytrulo | CIDP | Approved | Not disclosed | ▼ |
| Empasiprubart | Kidney transplant rejection | Phase 2 | Not disclosed | ▼ |
What does argenx SE do?
argenx developed Vyvgart which lowers harmful antibody levels by blocking FcRn receptor. Approved for myasthenia gravis and tested for many autoimmune diseases. One of the most promising platform stories in biotech with over $3B cash. Key risk is competition from other FcRn drugs.
What to watch
CIDP Phase 3 data mid-2026
Vyvgart revenue growth
UCB competitive data
ITP results 2026
International launch
Investment thesis
Moderate RiskBull case
Dominant FcRn franchise with Vyvgart blockbuster. Same drug tested across CIDP ITP pemphigus myositis. Strong $3.2B cash. Peak sales exceed $8B. Platform validated across diseases.
Bear case
Intense FcRn competition. Label expansion failures possible. Pricing pressure. High valuation. Manufacturing complexity.
Risk factors
FcRn competition
Label expansion failures
Pricing pushback
Manufacturing challenges
Market access
Comparable companies
Sponsored
Get premium ARGX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you